Genetic Analysis AS
Genetic Analysis AS, a science-based diagnostic company, develops diagnostic solutions for human microbiome market in the United States, Europe, and internationally. It offers GA-map, a platform for the analysis of the human gut microbiota; GA-map Dysbiosis Test that detects and characterizes dysbiosis; and GA-map Analyzer, a cloud-based software solution. The company also provides GA-map Discove… Read more
Genetic Analysis AS (GEAN) - Total Assets
Latest total assets as of September 2025: Nkr43.84 Million NOK
Based on the latest financial reports, Genetic Analysis AS (GEAN) holds total assets worth Nkr43.84 Million NOK as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Genetic Analysis AS - Total Assets Trend (2020–2024)
This chart illustrates how Genetic Analysis AS’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Genetic Analysis AS - Asset Composition Analysis
Current Asset Composition (December 2024)
Genetic Analysis AS's total assets of Nkr43.84 Million consist of 51.2% current assets and 48.8% non-current assets.
| Asset Category | Amount (NOK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Nkr0.00 | 30.2% |
| Accounts Receivable | Nkr3.20 Million | 7.5% |
| Inventory | Nkr762.00K | 1.8% |
| Property, Plant & Equipment | Nkr0.00 | 0.0% |
| Intangible Assets | Nkr15.71 Million | 37.1% |
| Goodwill | Nkr0.00 | 0.0% |
Asset Composition Trend (2020–2024)
This chart illustrates how Genetic Analysis AS's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Genetic Analysis AS's current assets represent 51.2% of total assets in 2024, an increase from 50.4% in 2020.
- Cash Position: Cash and equivalents constituted 30.2% of total assets in 2024, down from 43.5% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 37.0% of total assets, a decrease from 46.0% in 2020.
- Asset Diversification: The largest asset category is intangible assets at 37.1% of total assets.
Genetic Analysis AS Competitors by Total Assets
Key competitors of Genetic Analysis AS based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ADCNF
OTCGREY:ADCNF
|
USA | $4.51 Billion |
|
Berry Genomics Co Ltd
SHE:000710
|
China | CN¥2.34 Billion |
|
Malaysian Genomics Resource
KLSE:0155
|
Malaysia | RM20.70 Million |
|
NSN Co. Ltd
KQ:031860
|
Korea | ₩60.96 Billion |
|
JOONGANG DNM Co.Ltd
KQ:051980
|
Korea | ₩121.79 Billion |
|
GeneMatrix Inc
KQ:109820
|
Korea | ₩28.03 Billion |
|
Genoray Co. Ltd
KQ:122310
|
Korea | ₩125.67 Billion |
|
Green Cross Lab Cell Corporation
KQ:144510
|
Korea | ₩565.79 Billion |
Genetic Analysis AS - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Genetic Analysis AS generates 0.37x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Genetic Analysis AS is currently not profitable relative to its asset base.
Genetic Analysis AS - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.13 | 2.26 | 1.83 |
| Quick Ratio | 3.08 | 2.10 | 1.71 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Nkr15.47 Million | Nkr 11.80 Million | Nkr 7.97 Million |
Genetic Analysis AS - Advanced Valuation Insights
This section examines the relationship between Genetic Analysis AS's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.66 |
| Latest Market Cap to Assets Ratio | 0.04 |
| Asset Growth Rate (YoY) | -20.8% |
| Total Assets | Nkr42.38 Million |
| Market Capitalization | $1.89 Million USD |
Valuation Analysis
Below Book Valuation: The market values Genetic Analysis AS's assets below their book value (0.04 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Genetic Analysis AS's assets decreased by 20.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Genetic Analysis AS (2020–2024)
The table below shows the annual total assets of Genetic Analysis AS from 2020 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | Nkr42.38 Million | -20.78% |
| 2023-12-31 | Nkr53.49 Million | -16.97% |
| 2022-12-31 | Nkr64.42 Million | -22.84% |
| 2021-12-31 | Nkr83.49 Million | +50.11% |
| 2020-12-31 | Nkr55.62 Million | -- |